Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
162
-
Total 13F shares, excl. options
-
98.2M
-
Shares change
-
-19.4M
-
Total reported value, excl. options
-
$96.7M
-
Value change
-
-$25.8M
-
Put/Call ratio
-
4.32
-
Number of buys
-
71
-
Number of sells
-
-72
-
Price
-
$0.98
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q2 2025
202 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2025.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 162 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 98.2M shares
of 207M outstanding shares and own 47.35% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (14.7M shares), VANGUARD GROUP INC (11.7M shares), WASATCH ADVISORS LP (10.3M shares), Two Seas Capital LP (9.95M shares), PenderFund Capital Management Ltd. (6.68M shares), MARSHALL WACE, LLP (5.31M shares), GEODE CAPITAL MANAGEMENT, LLC (4.58M shares), STATE STREET CORP (3.76M shares), Indaba Capital Management, L.P. (3M shares), and CITADEL ADVISORS LLC (2.33M shares).
This table shows the top 162 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.